All In MedTech

Device Trial Radar · NCT02833402

Sacral Neuromodulation and the Microbiome

The Association Between the Urinary Microbiome and Response to Sacral Neuromodulation in Women With Urgency Urinary Incontinence

Last checked: Nov 19, 2026Latest source record: Nov 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Planned (sponsor's estimate)

Start

Dec 2016

Primary completion

Sep 2020

Study completion Sep 2020

Sponsor

Lead sponsor
Northwestern UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
American Urogynecologic Society; University of Pennsylvania; University of Missouri-Columbia; University of North Carolina; University of Washington; Saint Francis Hospital and Medical Center
First posted
Jul 14, 2016

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Sacral neuromodulation (SNM) which is approved as a treatment for men and women with urgency urinary incontinence (UUI), urgency frequency syndrome, urinary retention and anal incontinence, is a procedure designed to deliver electrical pulses to the sacral nerves, thereby influencing the bladder, sphincters, and pelvic floor. Although the success rates of this treatment are quite high, the precise mechanism of action of SNM in subjects with UUI remains unclear. Moreover, there are little data regarding specific patient characteristics that may serve as "predictors" for SNM success. Recent studies suggest that the bacterial community that lives in the urinary tract plays a role in the development and continuation of urinary symptoms. It is proposed that the urinary microbiome may change in women before and after SNM implantation and this study aims to describe these changes. Investigators in this study also hope to determine if differences in the urinary microbiome exist in women with a positive response to SNM treatment (responders) compared to those without symptom improvement (non-responders). This hypothesis will be tested by collecting urine samples as well as questionnaire and medical data from subjects with UUI that are already planning on undergoing SNM as part of clinical care before and after their SNM treatment.

Conditions

  • Urgency Urinary Incontinence

Interventions

  • InterStim TherapyDevice

    Sacral Neuromodulation, delivered by the InterStim® System, offers long-term control of bladder control and bowel control symptoms through modulation of the nerves that help control the pelvic floor and lower urinary tract.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The abundance of bacteria associated with inflammatory processes in the urinary tract of women with a positive response to SNM (responders) versus those without symptom improvement (non-responders)Time frame: 3 months after SNM treatment treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Northwestern University

    Chicago, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.